These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20079802)

  • 1. L-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model.
    Ordoñez-Librado JL; Anaya-Martinez V; Gutierrez-Valdez AL; Montiel-Flores E; Corona DR; Martinez-Fong D; Avila-Costa MR
    Neurosci Lett; 2010 Mar; 471(2):79-82. PubMed ID: 20079802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalation of divalent and trivalent manganese mixture induces a Parkinson's disease model: immunocytochemical and behavioral evidences.
    Ordoñez-Librado JL; Gutierrez-Valdez AL; Colín-Barenque L; Anaya-Martínez V; Díaz-Bech P; Avila-Costa MR
    Neuroscience; 2008 Jul; 155(1):7-16. PubMed ID: 18565681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manganese mixture inhalation is a reliable Parkinson disease model in rats.
    Sanchez-Betancourt J; Anaya-Martínez V; Gutierrez-Valdez AL; Ordoñez-Librado JL; Montiel-Flores E; Espinosa-Villanueva J; Reynoso-Erazo L; Avila-Costa MR
    Neurotoxicology; 2012 Oct; 33(5):1346-55. PubMed ID: 22975423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manganese inhalation as a Parkinson disease model.
    Ordoñez-Librado JL; Anaya-Martínez V; Gutierrez-Valdez AL; Colín-Barenque L; Montiel-Flores E; Avila-Costa MR
    Parkinsons Dis; 2010 Dec; 2011():612989. PubMed ID: 21209715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
    St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
    Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of curcumin with manganese may compromise metal and neurotransmitter homeostasis in the hippocampus of young mice.
    Schmitz AE; de Oliveira PA; de Souza LF; da Silva DG; Danielski S; Santos DB; de Almeida EA; Prediger RD; Fisher A; Farina M; Dafre AL
    Biol Trace Elem Res; 2014 Jun; 158(3):399-409. PubMed ID: 24723215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postnatal manganese exposure attenuates cocaine-induced locomotor activity and reduces dopamine transporters in adult male rats.
    Reichel CM; Wacan JJ; Farley CM; Stanley BJ; Crawford CA; McDougall SA
    Neurotoxicol Teratol; 2006; 28(3):323-32. PubMed ID: 16571372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Tomiyama M; Kimura T; Maeda T; Kannari K; Matsunaga M; Baba M
    Neurosci Res; 2005 Jun; 52(2):185-94. PubMed ID: 15893579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
    Luthra PM; Barodia SK; Raghubir R
    J Neurosci Methods; 2009 Apr; 178(2):284-90. PubMed ID: 19146880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.